PATENT CLAIM ANALYSIS

Application Number: 16047805
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-05
Patent Classification: ["514", "365000"]

Abstract:
Provided herein are methods of cancer treatment by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its structural analogs to a patient with cancer, for example, prostate, liver, lung, ovarian, breast, skin, colon (or rectum), stomach, pancreatic, kidney, bladder, soft tissue, or cervical cancer.

Claim (Index 10):
A method of stimulating the immune system in a patient with cancer, comprising administering a therapeutically effective amount of 2-(1\u2032H-indole-3\u2032-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) or a structural analog thereof to the patient, thereby treating the cancer,\n wherein the cancer is selected from a group consisting of skin, colorectal, stomach, pancreatic, kidney, bladder, soft tissue, and cervical cancer, and wherein said ITE has the formula:

Metadata:
- Claim Count in Document: 32.0
- Percentile: 95.0
- Lexical Diversity: 1.48077
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15613808', '14961325', '13952030', '13503657', '15509722']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7804469191136796
- 35 USC 102 Novelty (BERT): 0.6018442124628168
- Combined Prediction Score: 0.7625866484485933
- Mean Citation Score: 464.73619
- Max Citation Score: 555.94995
- Similarity Product: 443.8869671123385

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test